Forecast

The analysts' average price target is +28,63€ (+11,88%). The median is +30,91€ (+20,79%).

Buy	26
Hold	10
Sell	1

News Go to news feed

Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference

At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » More on de.investing.com
Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results

Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » More on de.investing.com
FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin

The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » More on de.investing.com

Financials

In the last quarter, Acadia Pharmaceuticals had revenue of 269.84m€ and net profit of 27.60m€

(EUR)	Jun 2026	YoY
Revenue	+269.84m	20,21%
Gross profit	+245.03m	18,44%
Net profit	+27.60m	22,00%
EBITDA	+28.35m	22,55%

Fundamentals

Metric	Value
Market capitalization	+4.37b€
Number of shares	171.24m
52-week high/low	+26,58€ - +16,91€
Dividends	No
Beta	0,85
P/E ratio	+13,21
PEG ratio	+0,19
P/B ratio	+3,90
P/S ratio	+4,47

Company profile

ACADIA Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von niedermolekularen Arzneimitteln konzentriert, die den ungedeckten medizinischen Bedarf bei Erkrankungen des zentralen Nervensystems decken. Das Unternehmen bietet NUPLAZID (Pimavanserin) zur Behandlung von Halluzinationen und Wahnvorstellungen im Zusammenhang mit der Psychose der Parkinson-Krankheit an. Die Pipeline des Unternehmens umfasst Pimavanserin, das sich in Phase 3 der Entwicklung für die Behandlung von Psychosen der Alzheimer-Krankheit und von Negativsymptomen der Schizophrenie befindet; Trofinetide, ein neuartiges synthetisches Analogon, das sich in Phase 3 der Entwicklung für die Behandlung des Rett-Syndroms befindet; ACP-044, ein neuartiges, oral verabreichtes Nicht-Opioid-Analgetikum, das sich in Phase 2 der Entwicklung zur Behandlung von akuten und chronischen Schmerzen befindet; und ACP-319, ein positiver allosterischer Modulator des Muscarinrezeptors, der sich in Phase 1 der Entwicklung zur Behandlung von Schizophrenie und kognitiven Störungen bei Alzheimer befindet. ACADIA Pharmaceuticals Inc. wurde 1993 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.

Name	Acadia Pharmaceuticals
CEO	Catherine E. Owen Adams
Headquarters	San Diego, ca USA
Website	acadia-pharm.com
Sector	Materials
Industry	Chemicals
IPO	05/27/2004
Employees	797